Trials / Completed
CompletedNCT00035425
Treatment of Neutropenic Patients With Fever Who Are Suspected to Have A Gram Positive Infection
A Randomized, Double-Blind Trial Comparing Linezolid To Vancomycin In The Empiric Treatment Of Febrile Neutropenic Oncology Patients With Suspected Gram-Positive Infections
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 120 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 13 Years
- Healthy volunteers
- Not accepted
Summary
This study will treat patients who have fever and neutropenia (after cancer chemotherapy) that is possibly due to a specific bacteria (gram positive bacteria).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | linezolid | 600mg every 12 hours |
| DRUG | vancomycin | 1gm every 12 hours. The dose of vancomycin intravenously may be adjusted for renal function, but the patient must be able to receive a 300 mL volume of intravenous fluid at the assigned dosing times of every 12 hours. |
Timeline
- Start date
- 2001-11-01
- Completion
- 2002-11-01
- First posted
- 2002-05-06
- Last updated
- 2009-12-01
Locations
40 sites across 10 countries: United States, Argentina, Brazil, Chile, Colombia, Finland, Mexico, Pakistan, Peru, Venezuela
Source: ClinicalTrials.gov record NCT00035425. Inclusion in this directory is not an endorsement.